van Netten J P, Algard F T, Coy P, Carlyle S J, Brigden M L, Thornton K R, To M P
Cancer. 1982 Jun 1;49(11):2383-8. doi: 10.1002/1097-0142(19820601)49:11<2383::aid-cncr2820491127>3.0.co;2-g.
Forty-milligram strips of malignant breast tissue were divided longitudinally into 20-mg microsamples. Soluble protein concentration was determined for one-half, and histologic evaluation for viable carcinoma content was made on its sister half. The correlation coefficient for 88 such comparisons was 0.330. This suggests that estrogen receptor (ER) assays that do not take into account the actual amount of carcinoma present in the sample may not permit reliable stratification of ER data. Using this technique, ER values obtained for 129 breast tumor microsamples were adjusted to reflect carcinoma content. A comparison of ER values before and after such adjustment revealed that the relative status of 73% was not significantly changed. The ER status of 27%, however, was changed sufficiently to be of potential clinical significance.
将40毫克的恶性乳腺组织条纵向切成20毫克的微量样本。对其中一半样本测定可溶性蛋白质浓度，对其另一半样本进行活癌含量的组织学评估。88次此类比较的相关系数为0.330。这表明，未考虑样本中实际癌含量的雌激素受体（ER）检测可能无法实现ER数据的可靠分层。使用该技术，对129个乳腺肿瘤微量样本获得的ER值进行调整以反映癌含量。此类调整前后的ER值比较显示，73%的相对状态没有显著变化。然而，27%的ER状态变化足以具有潜在临床意义。
